依达拉奉联合尼莫地平治疗高血压脑出血患者的疗效观察

Efficacy observation of edaravone combined with nimodipine on patients with hypertensive intracerebral hemorrhage

目的分析高血压脑出血患者联合应用依达拉奉与尼莫地平治疗的临床效果。方法100例高血压脑出血患者,通过随机数字表法分为对照组和观察组,每组50例。两组患者均实施常规治疗,对照组在常规治疗基础上应用尼莫地平治疗,观察组在对照组基础上应用依达拉奉治疗。比较两组患者的治疗效果、血肿体积和水肿体积改善情况、神经功能改善情况、生活质量改善情况。结果观察组治疗总有效率96.00%高于对照组的84.00%,差异有统计学意义(P<0.05)。治疗前,两组患者血肿体积、水肿体积比较,差异无统计学意义(P>0.05)。治疗后,两组患者血肿体积、水肿体积均小于本组治疗前,且观察组血肿体积(15.25±5.72)ml、水肿体积(14.25±4.33)ml均明显小于对照组的(19.87±6.54)、(20.33±3.27)ml,差异有统计学意义(P<0.05)。治疗前,两组患者美国国立卫生研究院卒中量表(NIHSS)评分比较,差异无统计学意义(P>0.05)。治疗后,两组患者NIHSS评分均明显低于本组治疗前,且观察组NIHSS评分(8.38±2.12)分低于对照组的(17.59±2.20)分,差异有统计学意义(P<0.05)。治疗前,两组患者社会功能、躯体功能、物质生活、心理功能评分比较,差异无统计学意义(P>0.05)。治疗后,两组患者社会功能、躯体功能、物质生活、心理功能评分均明显高于本组治疗前,且观察组社会功能、躯体功能、物质生活、心理功能评分分别为(86.06±5.75)、(82.75±4.09)、(81.64±5.43)、(80.70±5.88)分,高于对照组的(72.42±6.91)、(69.06±6.97)、(68.76±6.75)、(68.86±6.48)分,差异有统计学意义(P<0.05)。结论高血压脑出血患者应用依达拉奉联合尼莫地平治疗可获得突出效果,不仅能够改善患者血肿体积和水肿体积,还可改善患者神经功能和生活质量,利于患者病情康复,值得临床推广。

Objective To analyze the clinical effect of edaravone combined with nimodipine on patients with hypertensive intracerebral hemorrhage.Methods A total of 100 patients with hypertensive intracerebral hemorrhage were divided into control group and observation group according to the random numerical table,with 50 cases in each group.Both groups received conventional treatment,on this basis,the control group was treated with nimodipine,and the observation group was treated with edaravone on the basis of the control group.Both groups were compared in terms of therapeutic effect,the improvement of hematoma volume and edema volume,the improvement of neurological function,and the improvement of quality of life.Results The total effective rate of treatment was 96.00%in the observation group,which was higher than that of 84.00%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the two groups in terms of hematoma volume and edema volume(P>0.05).After treatment,the hematoma volume and edema volume in both groups were smaller than those before treatment in this group;the hematoma volume of(15.25±5.72)ml and edema volume of(14.25±4.33)ml in the observation group were significantly smaller than those of(19.87±6.54)and(20.33±3.27)ml in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the two groups in National Institutes of Health Stroke Scale(NIHSS)score(P>0.05).After treatment,the NIHSS scores in both groups were significantly lower than those before treatment in this group,and the NIHSS score of(8.38±2.12)points in the observation group was lower than that of(17.59±2.20)points in the control group.The differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the scores of social function,somatic function,physical life,and psychological function between the two groups(P>0.05).After treatment,the scores of social function,somatic function,physical life,and psychological function in both groups were significantly higher than those before treatment in this group;the scores of social function,somatic function,physical life,and psychological function of the observation group were(86.06±5.75),(82.75±4.09),(81.64±5.43),and(80.70±5.88)points,which were higher than those of(72.42±6.91),(69.06±6.97),(68.76±6.75),and(68.86±6.48)points in the control group;the differences were statistically significant(P<0.05).Conclusion The combined treatment of edaravone and nimodipine for patients with hypertensive intracerebral hemorrhage can obtain outstanding effect,which can not only improve the volume of hematoma and edema,but also improve the neurological function and quality of life of patients,which is conducive to the rehabilitation of patients,and is worthy of clinical promotion.